Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04992104
Other study ID # CTOREB3512
Secondary ID MRT-168043
Status Recruiting
Phase
First received
Last updated
Start date February 22, 2023
Est. completion date December 2024

Study information

Verified date April 2023
Source The Hospital for Sick Children
Contact Jessie Hulst, MD
Phone 416-813-7735
Email jessie.hulst@sickkids.ca
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is being conducted to investigate how a mother's nutritional status and her gut microbiome during pregnancy contribute to the birth outcomes and health of her baby. The gut microbiome is the totality of microorganisms (e.g. bacteria, viruses, fungi) living in the gastrointestinal tract. This study will focus on pregnant women, 24 years and younger living in the Toronto and greater Toronto area. The focus is on younger women due to their vulnerability to undernutrition. Pregnant participants, and upon delivery, their newborns will be followed throughout pregnancy and for a year afterwards. Throughout this period, the investigators will collect stool samples, rectal swabs, blood samples, health assessments, nutritional and dietary assessments and birth/ labour details. The goal is to define the relationship between a mother's nutritional status and her microbiome dynamics during pregnancy and how they contribute to the birth outcomes and growth of her newborn. With the hypothesis that alterations of the microbiota in the maternal gut (dysbiosis) exacerbated by nutritional status or pathogen exposure during pregnancy, impacts weight gain because of impaired nutrient absorption, leading to corresponding negative birth outcomes.


Description:

This project represents the first systematic investigation of the impact of the microbiome on nutritional status during pregnancy in young women and directly aligns with global health initiatives focused on this vulnerable cohort. The goal of the study is to define the relationships between host nutritional status and microbiome dynamics during pregnancy and how they contribute to birth outcomes. The gut microbiome has a profound influence on host nutritional status. Dysbiosis (loss of diversity/beneficial microbes and gain of pathobionts) has emerged as a major factor in the development of undernutrition. Despite the importance of nutrition during pregnancy, few studies have examined the role of the microbiome on maternal health and birth outcomes. Further, little is known concerning the influence of enteric eukaryotic microbes, such as parasites, on the bacterial microbiome and host nutrition. At the core of this study are two complementary cohorts of young women that provide an exceptional opportunity to obtain longitudinal samples to monitor the dynamic relationships between microbiome community structure and function with gut health and host nutritional status. This registration is for the the Toronto cohort of the study, which will focus on refugee and young adult obstetric clinics in Toronto, a population of specific relevance to undernutrition. This cohort is expected to yield insights into the influence of eukaryotic microbes that are often viewed as asymptomatic. The target demographic of the study is young mothers, 24 years of age and younger, in the Toronto and Greater Toronto Area. The investigators have identified this younger demographic due to the lack of knowledge on the microbiome of young women, and their vulnerability to undernutrition. A second complementary cohort will be based in the Matiari district of Pakistan. This project will yield unprecedented insights into the relationships between prokaryotic and eukaryotic microbes in the gut and their associations with maternal health and birth outcomes. The central hypothesis of the study is that alterations of the microbiota in the maternal gut (dysbiosis) exacerbated by nutritional status or pathogen exposure during pregnancy, impacts weight gain because of impaired nutrient absorption, leading to corresponding negative birth outcomes. The study will be a prospective, longitudinal, observational study to investigate the impact and relationship between prokaryotic and eukaryotic microbes in the gut and their association with maternal health and birth outcomes among young women, 24 years of age and younger in the Toronto and Greater Toronto Area. The study will aim to recruit 400 women into two groups based on BMI at time of recruitment (Normal BMI will be defined as between 20 and 24.9 kg/m2 and Low BMI will be defined as less than 20 kg/m2). With a goal of having 200 participants within the normal BMI group and 200 participants within the low BMI group. Although this is the recruitment aim, in the event that the investigators are unable to recruit 200 women with a low BMI, more women will be recruited that fall within the normal BMI range. The study will follow women and their infants over the course of their pregnancy and for a year post-partum, collecting stool, rectal and blood samples, nutritional information, heath assessments, anthropometric measurements and empowerment metrics at different time points.


Recruitment information / eligibility

Status Recruiting
Enrollment 800
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender Female
Age group N/A to 24 Years
Eligibility Inclusion Criteria: 1. Consent provided 2. Participant is between 8-20 weeks post-conception 3. Female aged 24 years of age and younger 4. Confirmation of pregnancy 5. Intend to comply with study procedures and follow up Exclusion Criteria: 1. Women who do not meet the enrolment age criteria 2. Women who are 20 + weeks post-conception 3. Women who have taken antibiotics within the past 3 months Note: it is common practice to give the mother penicillin in perinatal period if they are GBS positive; because this is standardized across the board it would not act as an exclusion factor.

Study Design


Locations

Country Name City State
Canada St. Michael's Hospital Toronto
Canada The Hospital for Sick Children Toronto

Sponsors (9)

Lead Sponsor Collaborator
The Hospital for Sick Children Aga Khan University, Canadian Institutes of Health Research (CIHR), Dalhousie University, National Institute of Allergy and Infectious Diseases (NIAID), Unity Health Toronto, University of Alberta, University of Calgary, University of Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess if alterations of the microbiota in the maternal gut (dysbiosis) are associated with changes in maternal gestational weight gain. The primary endpoint will be the change in maternal gestational weight gain (GWG) during pregnancy, measured between the first (8-20 weeks post-conception) and second time point (30-34 weeks post conception). 8-20 weeks post-conception, 30-34 weeks post conception
Secondary Anthropometrics: Maternal BMI calculated using weight and height; BMI = kg/m2 8-20 weeks post-conception, 30-34 weeks post-conception, delivery, 3-months post-partum, 6 months post-partum and 12 months post-partum
Secondary Anthropometrics: Maternal middle upper arm circumference Measured in cm 8-20 weeks post-conception, 30-34 weeks post-conception, 3-months post-partum,and 12 months post-partum
Secondary Anthropometrics: Maternal triceps skinfold thickness Measured in cm 8-20 weeks post-conception, 30-34 weeks post-conception, 3-months post-partum, and 12 months post-partum
Secondary Anthropometrics: Maternal height Measured in cm 8-20 weeks post conception, 30-34 weeks post conception, delivery, 3 months post-partum and 12 months post partum
Secondary Anthropometrics: Maternal weight Measured in kg 8-20 weeks post conception, 30-34 weeks post conception, delivery, 3 months post-partum and 12 months post-partum
Secondary Maternal blood biomarkers Concentration of HB + MCV, ferritin, and CRP 8-20 weeks post-conception, 30-34 weeks post-conception, and 12 months post-partum
Secondary Infant blood biomarkers Concentration of HB + MCV, ferritin, and CRP 12 months
Secondary Infant sex Female or Male Determined at delivery
Secondary Infant morbidity Assessed through infant health assessment questionnaires 3 months, 6 months and 12 months
Secondary Maternal morbidity Assessed through health assessment questionnaires 8-20 weeks post-conception, 30-34 weeks post-conception, 3 months post-partum, 6 months post-partum and 12 months post-partum
Secondary Infant growth: weight Measured in kg within 24 hours of birth, 3 months, 6 months and 12 months
Secondary Infant growth: length Measured in cm within 24 hours of birth, 3 months, 6 months and 12 months
Secondary Infant growth: head circumference Measured in cm within 24 hours of birth, 3 months, 6 months and 12 months
Secondary Infant growth: mid upper arm circumference Measured in cm within 24 hours of birth, 3 months, 6 months and 12 months
Secondary Infant growth: triceps skinfold thickness Measured in cm within 24 hours of birth, 3 months, 6 months and 12 months
Secondary Infant Gestational age Will be documented at baseline visit. 8-20 weeks post conception
Secondary Breast feeding: amount and initiation of complementary feeding Based off of WHO 2010 Guidelines: Indicators for assessing infant and young child feeding practices (Part 2 Measurement) within 24 hours of birth, 3 months, 6 months and 12 months
Secondary Maternal age 24 years or younger Documented at 8-20 weeks post-conception
Secondary Reported maternal medication use [Questionnaire] 8-20 weeks post-conception, 30-34 weeks post-conception, within 24 hours of delivery, 3-months post-partum, 6 months post-partum and 12 months post-partum
Secondary Reported Infant medication use [Questionnaire] within 24 hours of birth, 3 months, 6 months and 12 months
Secondary Maternal dietary intake Assessed through ASA 24 HR Dietary Recall system, completed 2x each time point 8-20 weeks post conception, 30-34 weeks post conception and 12 months post partum
Secondary Dietary diversity Minimum Dietary Diversity Score for Women (MDD-W) 8-20 weeks post conception, 30-34 weeks post conception, 3 months post-partum and 12 months post partum
Secondary Household annual food insecurity Food insecurity will be assessed using the Household Food Insecurity Access Scale (HFIAS) 3 months post-partum and 12 months post-partum
Secondary Self-efficacy Self-efficacy will be measured using the Generalized Self-Efficacy scale, developed by Schwarzer and Jerusalem 3 months post-partum and 12 months post partum
Secondary Perceived decision making Questions pertaining to perceived decision-making are from the Pakistan Demographic and Health Survey (PDHS) 3 months post-partum and 12 months post partum
Secondary Perceived social support Perceived social support will be measured using the Multi-dimensional Scale of Perceived Social Support (MSPSS), developed by Zimet et al. 3 months post-partum and 12 months post partum
Secondary Maternal demographics Questions pertaining to demographic data are adapted from the Pakistan Demographic and Health Survey (PDHS) 8-20 weeks post-conception
Secondary Food insecurity Questionnaire developed by Hager, E.R., et al., Development and validity of a 2-item screen to identify families at risk for food insecurity. 8-20 weeks post conception, 3 months post partum and 12 months post partum
Secondary Perceived parental stress Perceived parental stress will be measured using the Perceived Stress Scale (PSS-10) 3 months post-partum and 12 months post partum
Secondary Preterm birth noted in labor and birth chart review Within 24 hours of birth
Secondary Stillbirth noted in labor and birth chart review Within 24 hours of birth
Secondary Small for gestational age noted in labor and birth chart review Within 24 hours of birth
Secondary Large for gestational age noted in labor and birth chart review Within 24 hours of birth
Secondary Birth size: length Measured in cm within 24 hours of birth
Secondary Birth size: head circumference Measured in cm within 24 hours of birth
Secondary Birth size: weight Measured in kg within 24 hours of birth
Secondary Birth defects Assessed within 24 hours of birth within 24 hours of birth
Secondary Delivery assessment Assessed within 24 hours of birth within 24 hours of birth
Secondary Infant dietary intake: NutricheQ Questionnaire NutricheQ questionnaire: a tool designed for toddlers aged 1 to 3 years of age, with a focus on markers for inadequate or excessive intake and dietary imbalances 12 months
Secondary Maternal stool biomarkers: Calprotectin, Lipocalin and Claudin 15 Markers in the stool for intestinal mass, inflammation, and gut permeability and circulating lipopolysaccharide, among other markers 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum
Secondary Infant Stool biomarkers: Calprotectin, Lipocalin and Claudin 15 Markers in the stool for intestinal mass, inflammation, and gut permeability and circulating lipopolysaccharide, among other markers 3 months and 12 months
Secondary Maternal: incidence of pathobionts As identified through 16S, 18S and ITS rDNA surveys 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum
Secondary Infant: incidence of pathobionts As identified through 16S, 18S and ITS rDNA surveys 3 months and 12 months
Secondary Maternal: metabolomic profile of stool (metabolites involved in central metabolism as analysed by Mass Spectrometry) Analysis of the core metabolites involved in central metabolism. These metabolites will be analysed through Mass Spec and include short chain fatty acids, amino acids, intermediates in energy metabolism and nucleotide biosynthesis 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum
Secondary Maternal gut bacteria profile as measured through 16S rDNA sequence surveys measured through 16S rDNA sequence surveys 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum
Secondary Maternal: blood metallomics profile as measured through ICP-MS (https://www.metabolomicscentre.ca/new_service/25) TMIC Metallomics Platform to be used. 8-20 weeks post conception, 30-34 weeks post conception, and 12 months post partum
Secondary Infant: blood metallomics profile as measured through ICP-MS (https://www.metabolomicscentre.ca/new_service/25) Through TMIC platform 12 months
Secondary Infant: gut bacterial profile as measured through 16S rDNA sequence surveys measured through 16S rDNA sequence surveys 3 and 12 months post partum
Secondary Maternal metabolic pathway expression profile as measured through whole microbiome RNASeq (metatranscriptomics) measured through whole microbiome RNASeq (metatranscriptomics) 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum
Secondary Infant eukaryotic microbiome profile as measured through 18S and ITS rDNA sequence surveys measured through 18S and ITS rDNA sequence surveys 3 months and 12 months
Secondary Maternal eukaryotic microbiome profile as measured through 18S and ITS rDNA sequence surveys measured through 18S and ITS rDNA sequence surveys 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum
Secondary Maternal bacterial gene expression profile as measured through whole microbiome RNASeq (metatranscriptomics) The output of these analyses are readouts of microbial gene expression detailing biochemical activities as well as the taxa responsible. 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum
Secondary Maternal: microbiome taxonomic alpha and beta diversity To define taxonomic diversity, species profiles from 16S, 18S and ITS rDNA data will be clustered to identify differences in community structure across samples. Alpha diversity will be measured through indices such as Chao, Shannon and Simpson indices. Beta diversity will be measured through standard indices such as Bray-Curtis distances. 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum
Secondary Infant: microbiome taxonomic alpha and beta diversity To define taxonomic diversity, species profiles from 16S, 18S and ITS rDNA data will be clustered to identify differences in community structure across samples. Alpha diversity will be measured through indices such as Chao, Shannon and Simpson indices. Beta diversity will be measured through standard indices such as Bray-Curtis distances. 3 months and 12 months
See also
  Status Clinical Trial Phase
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Completed NCT03284515 - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Recruiting NCT04278651 - Early Antenatal Support for Iron Deficiency Anemia Phase 4
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT06258902 - Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
Completed NCT05487196 - Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia Phase 2
Completed NCT03750968 - Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects Phase 2
Enrolling by invitation NCT06127277 - Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care N/A
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT06069856 - Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06069869 - Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Not yet recruiting NCT06079918 - Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania Phase 3